The FDA approved bevacizumab-vikg (Lytenava), the first formulation of the cancer drug Avastin specifically for wet age-related macular degeneration, ending 20 years of off-label use. The move could raise costs for patients, as the branded version may be priced around $625 per dose in the UK compared to $50-60 for compounded versions. Meanwhile, the agency also cleared a new over-the-counter pain reliever, Tylenol with Naproxen, the first fixed-dose combo of acetaminophen...